AbbVie (ABBV) Enterprise Value (2012 - 2026)

AbbVie (ABBV) has reported Enterprise Value for 15 consecutive years, with $438.2 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Enterprise Value rose 36.29% year-over-year to $438.2 billion in Q2 2026; TTM through Jun 2026 was $438.2 billion, a 36.29% increase from a year earlier, with the FY2025 full-year figure at $398.8 billion, up 29.4% from the prior year.
• Enterprise Value was $438.2 billion for Q2 2026 at AbbVie, up from $374.9 billion in the prior quarter.
• Over five years, Enterprise Value peaked at $438.2 billion in Q2 2026 and troughed at $225.5 billion in Q3 2022.
• A 5-year average of $311.2 billion and a median of $296.7 billion in 2024 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value jumped 53.77% in 2022 and slipped 12.19% in 2023, its largest moves.
• Over 5 years, Enterprise Value stood at $276.8 billion in 2022, then fell by 5.7% to $261.0 billion in 2023, then grew by 18.09% to $308.2 billion in 2024, then rose by 29.4% to $398.8 billion in 2025, then rose by 9.87% to $438.2 billion in 2026.
• The last three Enterprise Value figures came in at $438.2 billion (Q2 2026), $374.9 billion (Q1 2026), and $398.8 billion (Q4 2025), per Business Quant data.